精神心理科

订阅

MedSci主页 / 所有栏目 / 精神心理科

NEJM：丁丙诺啡可用于治疗新生儿戒断综合征，比吗啡更好！

2017-06-15 MedSci MedSci原创

丁丙诺啡新生儿戒断综合征
关注

目前用吗啡治疗新生儿节戒断综合征，药物治疗持续时间较长且需住院治疗。对该适应症，丁丙诺啡可能比吗啡更有效。

目前用吗啡治疗新生儿节戒断综合征，药物治疗持续时间较长且需住院治疗。对该适应症，丁丙诺啡可能比吗啡更有效。

采用单点、双盲、双模拟临床试验，我们随机分配了63名足月婴儿(妊娠≥37周)，他们在出生之前接触了阿片类药物，并且有新生儿戒断综合症的症状。对他们进行舌下服用丁诺啡或口服吗啡治疗。在接触阿片类药物的情况下，没有使用最大剂量的阿片类药物的婴儿辅助苯巴比妥治疗。主要的观察终点是新生儿阿片类药物戒断症状的治疗持续时间。次要临床终点是住院时间的长短，需要辅助苯巴比妥治疗的婴儿的比例，以及安全性。

与吗啡相比，丁丙诺啡治疗新生儿戒断综合征的平均时间明显缩短(15天vs.28天)，住院治疗的平均时间也缩短了(21天vs.33天)(P小于0.001)。在治疗过程中，服用丁丙诺啡的33名婴儿中有5名(15%)辅助服用了苯巴比妥而服用吗啡的30名婴儿中有7名(23%)辅助服用了苯巴比妥(P=0.36)。在这两组中，不良事件发生率相似。

在患有新生儿戒断综合征的婴儿中，与口服吗啡相比，使用舌下服用丁丙诺啡治疗的患者，治疗时间较短，住院时间也较短，而且这两种药物的不良反应类似。

原始出处：
Walter K.Kraft，M.D.，Susan C.Adeniyi-Jones，et al. Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome. NEJM. 2017 June.
版权声明：本文系梅斯MedSci原创编译整理，未经本网站授权不得转载和使用。如需获取授权，请点击

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1992585, encodeId=06251992585d9, content=<a href='/topic/show?id=224054126c9' target=_blank style='color:#2F92EE;'>#戒断综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54126, encryptionId=224054126c9, topicName=戒断综合征)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqcyT7aQIuoYGGYr889lEiaOVWSfvMQ4d2oxhTMlWzEr6lPmg6pxzCVvPScSZrne4JFSyyPRCOxllQ/132, createdBy=416a2500064, createdName=ms3323097325231039, createdTime=Sun Mar 18 07:08:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346527, encodeId=568d134652e58, content=<a href='/topic/show?id=2013391531d' target=_blank style='color:#2F92EE;'>#吗啡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39153, encryptionId=2013391531d, topicName=吗啡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sat Jun 17 10:08:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430851, encodeId=c0961430851ce, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Jun 17 10:08:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602809, encodeId=486c1602809d9, content=<a href='/topic/show?id=94e819463d3' target=_blank style='color:#2F92EE;'>#丁丙诺啡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19463, encryptionId=94e819463d3, topicName=丁丙诺啡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e4218938219, createdName=xiaogang323, createdTime=Sat Jun 17 10:08:00 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
    2018-03-18 ms3323097325231039

    #戒断综合征#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1992585, encodeId=06251992585d9, content=<a href='/topic/show?id=224054126c9' target=_blank style='color:#2F92EE;'>#戒断综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54126, encryptionId=224054126c9, topicName=戒断综合征)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqcyT7aQIuoYGGYr889lEiaOVWSfvMQ4d2oxhTMlWzEr6lPmg6pxzCVvPScSZrne4JFSyyPRCOxllQ/132, createdBy=416a2500064, createdName=ms3323097325231039, createdTime=Sun Mar 18 07:08:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346527, encodeId=568d134652e58, content=<a href='/topic/show?id=2013391531d' target=_blank style='color:#2F92EE;'>#吗啡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39153, encryptionId=2013391531d, topicName=吗啡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sat Jun 17 10:08:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430851, encodeId=c0961430851ce, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Jun 17 10:08:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602809, encodeId=486c1602809d9, content=<a href='/topic/show?id=94e819463d3' target=_blank style='color:#2F92EE;'>#丁丙诺啡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19463, encryptionId=94e819463d3, topicName=丁丙诺啡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e4218938219, createdName=xiaogang323, createdTime=Sat Jun 17 10:08:00 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
    2017-06-17 showtest

    #吗啡#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1992585, encodeId=06251992585d9, content=<a href='/topic/show?id=224054126c9' target=_blank style='color:#2F92EE;'>#戒断综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54126, encryptionId=224054126c9, topicName=戒断综合征)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqcyT7aQIuoYGGYr889lEiaOVWSfvMQ4d2oxhTMlWzEr6lPmg6pxzCVvPScSZrne4JFSyyPRCOxllQ/132, createdBy=416a2500064, createdName=ms3323097325231039, createdTime=Sun Mar 18 07:08:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346527, encodeId=568d134652e58, content=<a href='/topic/show?id=2013391531d' target=_blank style='color:#2F92EE;'>#吗啡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39153, encryptionId=2013391531d, topicName=吗啡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sat Jun 17 10:08:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430851, encodeId=c0961430851ce, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Jun 17 10:08:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602809, encodeId=486c1602809d9, content=<a href='/topic/show?id=94e819463d3' target=_blank style='color:#2F92EE;'>#丁丙诺啡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19463, encryptionId=94e819463d3, topicName=丁丙诺啡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e4218938219, createdName=xiaogang323, createdTime=Sat Jun 17 10:08:00 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
    2017-06-17 zhouqu_8

    #综合征#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1992585, encodeId=06251992585d9, content=<a href='/topic/show?id=224054126c9' target=_blank style='color:#2F92EE;'>#戒断综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54126, encryptionId=224054126c9, topicName=戒断综合征)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqcyT7aQIuoYGGYr889lEiaOVWSfvMQ4d2oxhTMlWzEr6lPmg6pxzCVvPScSZrne4JFSyyPRCOxllQ/132, createdBy=416a2500064, createdName=ms3323097325231039, createdTime=Sun Mar 18 07:08:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346527, encodeId=568d134652e58, content=<a href='/topic/show?id=2013391531d' target=_blank style='color:#2F92EE;'>#吗啡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39153, encryptionId=2013391531d, topicName=吗啡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sat Jun 17 10:08:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430851, encodeId=c0961430851ce, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Jun 17 10:08:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602809, encodeId=486c1602809d9, content=<a href='/topic/show?id=94e819463d3' target=_blank style='color:#2F92EE;'>#丁丙诺啡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19463, encryptionId=94e819463d3, topicName=丁丙诺啡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e4218938219, createdName=xiaogang323, createdTime=Sat Jun 17 10:08:00 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
    2017-06-17 xiaogang323

    #丁丙诺啡#

    0

相关资讯

Zubsolv获准用于治疗阿片类依赖患者

圣路易斯(MD Consult)——2013年7月4日，Orexo公司宣布，美国食品药品管理局(FDA)已批准Zubsolv(丁丙诺啡/纳洛酮)用于阿片类依赖患者的维持治疗。该药物将作为包括咨询和社会心理支持在内的完整治疗计划的一部分。 根据该产品标签，Zubsolv属于阿片受体部分激动剂，剂型为薄荷口味的舌下速溶片，每日用药1次。Orexo公司称，与其他丁丙诺啡/纳洛酮药物相比，

Sci Transl Med：丁丙诺啡和纳曲酮结合阻止可卡因成瘾

丁丙诺啡（Buprenorphine）是一种可激活μ和κ阿片受体的合成阿片类药物。它可以减少阿片类药物瘾君子可卡因的用量。然而，丁丙诺啡对μ阿片受体强有力的激动剂效应，使得它有可能造成非阿片依赖的可卡因滥用者对阿片的依赖。 研究者假设，结合丁丙诺啡和纳曲酮（naltrexone一种强力μ类阿片拮抗剂，同时具有较弱的δ和κ拮抗剂效果）可以阻止可卡因成瘾，同时避免产生阿片依赖。 研究者利用大鼠，对

JAMA：阿片类药物戒断治疗，丁丙诺啡舌下含服还是皮下植入？

由于服药依从性差、滥用和转移使得丁丙诺啡治疗阿片类药物依赖的效果十分有限。本研究旨在确定作为稳定戒断阿片类药物的依赖者的维持治疗使用丁丙诺啡植入剂治疗的效果是否劣于丁丙诺啡每日舌下含化的效果，治疗时间为6个月。2014年6月26日至2015年5月18日在美国 21个地区进行随机、活性对照、双盲双虚拟研究设计，纳入的研究对象为门诊患者。这些患者按处方每日舌下含服丁丙诺啡6个月及以上，每日舌下含服≤8

Lancet Psychiatry：阿片类药物替代疗法（美沙酮vs丁丙诺啡）的死亡风险比较

阿片类药物依赖性增加了过早死亡的风险。使用美沙酮或丁丙诺啡替代阿片类药物治疗可降低死亡风险，尤其是对与药物过量有关的死亡。临床指南推荐美沙酮作为阿片类药物替代治疗的一线药物。该研究的目的是测试丁丙诺啡治疗是否比美沙酮治疗具有较低的死亡风险，通过比较在治疗诱导时，治疗过程药物的转换和治疗后停止用药的全因死亡率进行分析。研究人员在澳大利亚新南威尔士州做了一项所有具有阿片类药物依赖性患者的回顾性队列研究

NEJM：丁丙诺啡治疗新生儿戒断综合征!

在新生儿戒断综合征的患儿中，舌下含服丁丙诺啡的治疗与口服吗啡相比，治疗时间更短，住院时间也缩短，而不良事件发生率相似。